- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01459120
Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho (DoDoPi)
Comparing Door-to-door Versus Community Gathering in Providing HIV Counseling and Testing Within an Integrated Primary Health Care Package: a Cluster Randomized Trial in Rural Lesotho
Study Overview
Status
Intervention / Treatment
Detailed Description
12 health centers (clusters) in rural Lesotho are matched according to their routine performance in VCT and enrollment into chronic HIV/AIDS care (average numbers tested positive and enrolled into HIV/AIDS care per month per facility). After matching, 6 health centers are randomly assigned to perform door-to-door VCT, whereas the others perform the traditional community gathering approach (called "pitso" in Sesotho). Within the catchment area of each health center five campaigns in five different, randomly selected villages, are held (one day VCT campaign per village). Within each cluster another five villages are randomly selected who do not get a particular campaign and serve as a control for each cluster. In each matched cluster-pair, both health centers conduct the five campaigns during the same week (one conducting it as door-to-door, the other one conducting it through "pitsos" (community gathering)).
Both approaches receive the same resources in terms of finances, time spending doing the VCT-campaign and human resources.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Thaba-Tseka, Lesotho
- Paray Hospital
-
-
Botha-Bothe
-
Seboche, Botha-Bothe, Lesotho, P.O. 304
- Seboche Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Not already known to be HIV-positive
- Resident in the catchment area of the health center where the campaign is conducted
- Provision of written informed consent to participate (signed by writing or fingerprint)
- In case of children: Provision of written informed consent by an adult care-taker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Door-to-Door
Health care workers propose the integrated service package including VCT at the peoples' homes.
|
Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
|
|
Active Comparator: Pitso
Health care workers propose the integrated service package including VCT through community gatherings ("pitso").
|
Health care workers propose the integrated service package including VCT through community gatherings ("Pitso").
|
|
No Intervention: control
Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level.
These villages get no particular intervention (VCT-campaign).
However, routine services continue to be provided.
These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of newly tested HIV-positive clients over all clients tested for HIV during the campaigns
|
Proportion refers to the proportion of newly tested HIV-positive clients among all clients tested for HIV during the voluntary counselling and testing campaigns in each arm.
|
|
|
Proportion of clients newly tested HIV-positive who enrolled into HIV/AIDS care within one month over all clients newly tested HIV-positive during the campaigns
Time Frame: 4 weeks after tested positive
|
One month after the campaigns, enrollment of clients who newly tested HIV-positive at the campaign is assessed at the facilities based on the clinics' registers.
|
4 weeks after tested positive
|
|
Overall number newly tested HIV-positive and enrolled into chronic HIV/AIDS-care at each facility
Time Frame: 4 weeks after campaign
|
Between the two study-arms, the overall numbers will be compared in two ways:
|
4 weeks after campaign
|
|
Absolute number of newly tested HIV-positive clients
|
Refers to the overall number newly tested HIV-positive during the campaigns in both arms
|
|
|
Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care
Time Frame: 4 weeks after tested HIV-positive
|
This refers to the absolute number newly tested HIV-positive during the campaigns who enrolled thereafter into chronic HIV/AIDS care within one month
|
4 weeks after tested HIV-positive
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CD4-count among clients newly tested HIV-positive
|
CD4-counts will be measured on site using a Point-of-care machine.
|
|
|
Clinical WHO-stage among clients newly tested HIV-positive
|
||
|
Proportion of clients screened positive for Tuberculosis during the campaigns
|
All clients accessing services (irrespective of HIV-status) will be screened for TB by a nurse.
Clients with a positive screening are provided sputum bottles and are entered in the Tuberculosis-suspect register.
|
|
|
Proportion of first-time HIV-testers among all clients accessing the testing services
|
||
|
Proportion of clients with positive tuberculosis screening who return 3 sputum-bottles within ≤ 5 days to the facility
Time Frame: 5 days after the campaign was held
|
Tuberculosis-suspect registers and tuberculosis registers at the facility are used for verification
|
5 days after the campaign was held
|
|
Proportion of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.
Time Frame: 5 days after the campaign was held
|
Tuberculosis suspect registers and Tuberculosis registers at the facility are used for verification.
|
5 days after the campaign was held
|
|
Demographic characteristics of clients accessing the voluntary counseling and testing services
|
||
|
Absolute number of clients accessing the services at the campaigns who have a positive screening for Tuberculosis
|
||
|
Absolute number of clients with positive tuberculosis screening who return 3 sputum-bottles within ≤ 5 days to the facility
Time Frame: ≤ 5 days after the campaigns
|
≤ 5 days after the campaigns
|
|
|
Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.
Time Frame: ≤ 5 days after the campaign
|
≤ 5 days after the campaign
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Motlomelo Masetsibi, SolidarMed
- Study Director: Niklaus Labhardt, MD, MIH, SolidarMed
- Study Chair: Karolin Pfeiffer, MD, McommH, SolidarMed
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Slow Virus Diseases
- HIV Infections
- Hypertension
- Tuberculosis
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- DoDoPi-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Door-to-door
-
Seva FoundationQueen's University, Belfast; Dr Shroff's Charity Eye Hospital; Indian Institute... and other collaboratorsCompleted
-
University of Mogi das CruzesCompleted
-
Washington University School of MedicineCompletedCommunication | Behavior and Behavior MechanismsUnited States
-
Open Door Young People's ServiceUnknownParent-Child RelationsUnited Kingdom
-
Onward Health, IncNational Institute on Aging (NIA)RecruitingDementia | Cognitive Decline | Alzheimer Disease or Associated DisorderUnited States
-
University of Mogi das CruzesCompletedHand Injuries and DisordersBrazil
-
Maastricht University Medical CenterRecruiting
-
Xijing HospitalFirst Affiliated Hospital Xi'an Jiaotong University; Tang-Du Hospital; Xi'an...RecruitingCervical Spinal StenosisChina
-
Geisinger ClinicCompletedHealth Behavior | TelehealthUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou First People's Hospital; The Third Affiliated Hospital of Southern... and other collaboratorsNot yet recruitingCervical Spondylotic Myelopathy